NICE recommends against Aimovig from Novartis

The U.K.’s NICE issued draft guidance not recommending Aimovig erenumab from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent chronic and episodic

Read the full 207 word article

User Sign In